Literature DB >> 2064772

Use of a focal infectivity assay for testing susceptibility of HIV to antiviral agents.

S H Pincus1, K Wehrly, B Chesebro.   

Abstract

A highly sensitive and quantitative focal immunoassay has been developed for detecting the human immunodeficiency virus (HIV). The assay can be used to measure cell-free virus or the production of HIV by virus-infected cells. Both laboratory-adapted strains of HIV and patient isolates can be studied with this assay. In this communication, we demonstrate the utility of this assay for measuring the effects of anti-HIV agents on viral isolates. We show that the anti-viral effects of such diverse agents as azidothymidine, interferon-alpha, immunotoxins, soluble CD4 and antibody can be accurately quantified. This assay may be used in the discovery and evaluation of new anti-HIV therapies or may be adapted for use in testing the sensitivity of patient isolates to standard therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2064772

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  9 in total

1.  Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.

Authors:  S H Pincus; K G Messer; P L Nara; W A Blattner; G Colclough; M Reitz
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

2.  Sequences regulating tropism of human immunodeficiency virus type 1 for brain capillary endothelial cells map to a unique region on the viral genome.

Authors:  A V Moses; S G Stenglein; J G Strussenberg; K Wehrly; B Chesebro; J A Nelson
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

3.  Susceptibilities of simian immunodeficiency virus to protease inhibitors.

Authors:  Angelica C Giuffre; Joanne Higgins; Robert W Buckheit; Thomas W North
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

4.  Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.

Authors:  E J Platt; K Wehrly; S E Kuhmann; B Chesebro; D Kabat
Journal:  J Virol       Date:  1998-04       Impact factor: 5.103

5.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

6.  Human immunodeficiency virus infection of human brain capillary endothelial cells occurs via a CD4/galactosylceramide-independent mechanism.

Authors:  A V Moses; F E Bloom; C D Pauza; J A Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

7.  Analysis of ovine lentivirus infectivity and replication by using a focal immunoassay and an antigen-capture enzyme-linked immunosorbent assay.

Authors:  K A Marcom; S J Brodie; L D Pearson; J C DeMartini
Journal:  J Clin Microbiol       Date:  1992-11       Impact factor: 5.948

8.  Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.

Authors:  S H Pincus; J McClure
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

9.  Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.

Authors:  S H Pincus; K G Messer; S L Hu
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.